Peptides by condition · Weight, blood sugar, liver and gut

Peptides studied for fatty liver disease (MASH)

Checked against our study pages and the FDA labelsPublished by PepVault

Our library holds 15 study pages on fatty liver disease (MASH): 12 in people (all meta-analyses or randomized trials), and 3 in animals. They studied 8 compounds, with this many study pages each: Pemvidutide 4, Efinopegdutide 2, Tesamorelin 2, Semaglutide 1, Survodutide 1, Tirzepatide 1, Retatrutide 3 and HGH 1.

What the research on fatty liver disease (MASH) looks like

Fatty liver disease is fat building up in the liver, often alongside excess weight and type 2 diabetes. Its medical names have changed: MASLD is the fat itself, and MASH, once called NASH, is the form with inflammation that can scar the liver over time. The newer drugs that act on GLP-1 and glucagon have reached trials here.

These trials measure liver fat on an MRI scan, or take a small piece of liver (a biopsy) to see whether the inflammation cleared and whether scarring, called fibrosis, got worse. Clearing the inflammation without worse scarring is the result regulators look for.

A drop in liver fat on a scan is an early sign; a biopsy result after a year or more is stronger. Mouse models of fatty liver are built in different ways, so a result in one may not carry over to another, let alone to people.

Our study pages on fatty liver disease (MASH) by design: Trials in people 12, Other in people 0, Animals 3, Cells 0, of 15.Trials in people12Other in people0Animals3Cells0
How many of the 15 study pages on this condition reach each design, strongest at the top: meta-analyses and randomized trials in people, other studies in people, animals, cells.
A smiling woman in a dark training top in her kitchen, holding a glass of water

Model. Individual results vary.

PepVault for iPhone

Track your own progress in PepVault

Doses, vials, weight and side effects in one log.

Download on the App Store

7 days free on the yearly plan for new subscribers.

The 15 studies, by compound

Grouped by the compound each study is filed under, and within each, strongest design first. Each line gives the design, who was studied, how many and the year, before the finding.

  1. Pemvidutide

    3 in people · 1 in animals

    For fatty liver disease (MASH), 4 of our study pages are filed under Pemvidutide: 3 randomized trials in people, and 1 animal study (mice). The largest in people enrolled 212 people and was published in 2026. They were published from 2022 to 2026, in Lancet Gastroenterol Hepatol, Lancet, JHEP Rep and Sci Rep.

    Pemvidutide has no FDA-approved product: Drugs@FDA lists no application for it.

  2. Efinopegdutide

    2 in people

    For fatty liver disease (MASH), 2 of our study pages are filed under Efinopegdutide: 2 randomized trials in people. The largest in people enrolled 381 people and was published in 2026. They were published from 2023 to 2026, in Lancet and J Hepatol.

    Efinopegdutide has no FDA-approved product: Drugs@FDA lists no application for it.

  3. Tesamorelin

    2 in people

    For fatty liver disease (MASH), 2 of our study pages are filed under Tesamorelin: 2 randomized trials in people. The largest in people enrolled 50 people and was published in 2014. They were published from 2014 to 2020, in JAMA and JCI Insight.

    FDA-approved for other uses, not for fatty liver disease (MASH): Egrifta (injection) for reducing excess belly fat in adults with HIV and lipodystrophy (its label says it is not for weight loss).

  4. Semaglutide

    1 in people

    For fatty liver disease (MASH), 1 of our study pages is filed under Semaglutide: 1 randomized trial in people. It enrolled 1,197 people and was published in 2025, in N Engl J Med.

    FDA-approved, with a use tied to fatty liver disease (MASH) on its label: Wegovy (injection) for weight loss and keeping it off, lowering heart risk in adults with heart disease and excess weight, and a fatty-liver disease (MASH) with moderate to advanced scarring; Wegovy (tablet) for weight loss and keeping it off, and lowering heart risk in adults with heart disease and excess weight. Under Ozempic and Rybelsus it is approved for other uses.

  5. Survodutide

    1 in people

    For fatty liver disease (MASH), 1 of our study pages is filed under Survodutide: 1 randomized trial in people. It enrolled 216 people and was published in 2026, in Nat Med.

    Survodutide has no FDA-approved product: Drugs@FDA lists no application for it. FDA writes that it has warned companies that illegally sold unapproved drugs containing survodutide, among others, labeled “for research purposes”.

  6. Tirzepatide

    1 in people

    For fatty liver disease (MASH), 1 of our study pages is filed under Tirzepatide: 1 randomized trial in people. It enrolled 190 people and was published in 2024, in N Engl J Med.

    FDA-approved for other uses, not for fatty liver disease (MASH): Mounjaro (injection) for blood sugar control in type 2 diabetes (adults and children 10 and older), and lowering heart risk in adults with type 2 diabetes; Zepbound (injection) for weight loss and keeping it off, and moderate to severe obstructive sleep apnea in adults with obesity.

  7. Retatrutide

    1 in people · 2 in animals

    For fatty liver disease (MASH), 3 of our study pages are filed under Retatrutide: 1 randomized trial in people, and 2 animal studies (mice and hamsters). The largest in people enrolled 98 people and was published in 2024. They were published from 2024 to 2026, in Nat Med, Obesity (Silver Spring) and Am J Physiol Gastrointest Liver Physiol.

    Retatrutide has no FDA-approved product: Drugs@FDA lists no application for it, and FDA writes that it is not a component of any FDA-approved drug.

  8. HGH

    1 in people

    For fatty liver disease (MASH), 1 of our study pages is filed under HGH: 1 randomized trial in people. It enrolled 24 people and was published in 2021, in Clin Endocrinol (Oxf).

    FDA-approved for other uses, not for fatty liver disease (MASH): Humatrope (injection) for growth failure in children who make too little growth hormone and several other causes of short stature, and growth hormone deficiency in adults.

Side by side

For the 8 compounds on this page: studies in people, studies in animals or cells, the size of the largest study in people, and the FDA status from the labels our status pages read (a dash where they hold no record).

CompoundIn peopleAnimals or cellsLargest in peopleFDA
Pemvidutide31212Not approved
Efinopegdutide20381Not approved
Tesamorelin2050Approved for other uses
Semaglutide101,197Approved, a use tied to it
Survodutide10216Not approved
Tirzepatide10190Approved for other uses
Retatrutide1298Not approved
HGH1024Approved for other uses

What the studies did not show

Each study page names its own limits. These are the questions still open, in the study pages’ words.

This page is a reading of published studies, not medical advice. A diagnosis, and what to do about it, is a conversation with a clinician.

Questions

Which peptides have been studied for fatty liver disease (MASH)?

Our 15 study pages on fatty liver disease (MASH) are filed under 8 compounds, with this many each: Pemvidutide 4, Efinopegdutide 2, Tesamorelin 2, Semaglutide 1, Survodutide 1, Tirzepatide 1, Retatrutide 3 and HGH 1. Pemvidutide has the most.

Have any been tested in people with fatty liver disease (MASH)?

Yes: 12 of the 15 were in people, all of them meta-analyses or randomized trials (Pemvidutide, Efinopegdutide, Tesamorelin, Semaglutide, Survodutide, Tirzepatide, Retatrutide and HGH). The largest enrolled 1,197 people: “Semaglutide: MASH resolved in 62.9% vs 34.3% on placebo at 72 weeks” (2025).

Is any peptide FDA-approved for fatty liver disease (MASH)?

Yes, with a use tied to fatty liver disease (MASH) on their FDA labels: Semaglutide as Wegovy. 7 other compounds here with an FDA record have no use tied to it.

How large were the studies in people on fatty liver disease (MASH)?

Of the 12 in people, 11 give their size on our pages: 1 had 1,000 people or more, 6 had 100 to 999 and 4 had fewer than 100. The largest, a randomized trial from 2025, enrolled 1,197.

What did the animal and cell studies on fatty liver disease (MASH) use?

3 animal studies (mice and hamsters), filed under Retatrutide and Pemvidutide. A result in animals or cells shows what to test next, not what happens in a person.

What is the newest study on fatty liver disease (MASH) here?

Of our study pages on fatty liver disease (MASH), the newest is “Efinopegdutide: MASH resolved in up to 63% vs 13% on placebo”, a randomized trial in people published in 2026.

How this page was built

A study page is listed here only where we read its question, design and finding and the study was about this condition: its subjects had the condition, or were an animal or cell model of it, and the study gave them the compound. A study that only mentions the condition is not listed.

Studies are grouped by the compound each is filed under and ordered by design: meta-analyses and randomized trials in people first, then other studies in people, then animals, then cells, and within a group by size and then by year. The FDA status comes from the labels our legal-status and brand pages read.

Track it in the app

PepVault for iPhone

Track your own progress in PepVault

Doses, vials, weight and side effects in one log.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo